A shorter treatment gap is better when switching from natalizumab (Tysabri) to fingolimod (Gilenya)

A clinical trial published last week in the medical journalNeurology has shown that a reduced time period between treatments when switching from natalizumab (Tysabri) to fingolimod (Gilenya) is beneficial. To read the full article click on the following link

A shorter treatment gap

Article courtesy of MS Research Australia  www.msra.org.au